Advertisement

Molecular Neurobiology

, Volume 52, Issue 2, pp 805–810 | Cite as

Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes

  • Gregory F. OxenkrugEmail author
Article

Abstract

About 350 million people worldwide have type 2 diabetes (T2D). The major risk factor of T2D is impaired glucose tolerance (pre-diabetes) with 10 % of pre-diabetes subjects develop T2D every year. Understanding of mechanisms of development of T2D from pre-diabetes is important for prevention and treatment of T2D. Chronic stress and chronic low-grade inflammation are prominent risk factors for T2D development in pre-diabetic subjects. However, molecular mechanisms mediating effect of stress and inflammation on development of T2D from pre-diabetes remain unknown. One of such mechanisms might involve kynurenine (KYN) pathway (KP) of tryptophan (TRP) metabolism. We suggested that chronic stress- or chronic low-grade inflammation-induced upregulation of formation of upstream KTP metabolites, KYN and 3-hydroxyKYN, combined with chronic stress- or chronic low-grade inflammation-induced deficiency of pyridoxal 5′-phosphate, a co-factor of downstream enzymes of KTP, triggers overproduction of diabetogenic downstream KYN metabolites, kynurenic acid (KYNA) and 3-hydroxyKYNA (also known as xanthurenic acid (XA)). As the initial assessment of our working hypothesis, we evaluated plasma levels of up- and downstream KP metabolites in the same samples of T2D patients. KYN, XA, and KYNA levels in plasma samples of T2D patients were higher than in samples of non-diabetic subjects. Our results provide further support of “kynurenine hypothesis of insulin resistance and its progression to T2D” that suggested that overproduction of diabetogenic KP metabolites, induced by chronic stress or chronic low-grade inflammation, is one of the mechanisms promoting development of T2D from pre-diabetes. Downstream metabolites of KP might serve as biomarkers of T2D and targets for clinical intervention.

Keywords

Type 2 diabetes Tryptophan Kynurenines Xanthurenic acid Kynurenic acid Stress Inflammation 

Abbreviations

T2D

Type 2 diabetes

IR

Insulin resistance

TRP

Tryptophan

NAD

Nicotinamide adenine dinucleotide

IFNG

Interferon gamma

LPS

Lipopolysaccharide

KP

Kynurenine pathway of TRP metabolism

KYN

Kynurenine

KYNA

Kynurenic acid

3-HKYN

3-hydroxykynurenine

3-HKYNA

3-hydroxykynurenic acid

XA

Xanthurenic acid

3-HAA

3-hydroxyanthranilic acid

KMO

Kynurenine 3-monooxygenase

P5P

Pyridoxal 5′-phosphate

KAT

Kynurenine aminotransferase

KYNase

Kynureninase

IDO

Indoleamine-2,3-dioxygenase

TDO

Tryptophan-2,3-dioxygenase

HIV

Human immunodeficiency virus

HCV

Hepatitis C virus

HOMA

Homeostatic model assessment

Notes

Acknowledgments

This study is supported by NIMH104810. The author highly appreciates BioreclamationIVT, NY, USA, for providing plasma samples and Marieke van der Hart, PhD, for the excellent help with biochemical analyses

Conflict of Interest

The author declares that he has no competing interests.

References

  1. 1.
    Hackett RA, Steptoe A, Kumari M (2014) Association of diurnal patterns in salivary cortisol with type 2 diabetes in the Whitehall II study. J Clin Endocrinol Metab 99:4625–4631. doi: 10.1210/jc.2014-2459 PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72:219–246CrossRefPubMedGoogle Scholar
  3. 3.
    Connick JH, Stone TW (1985) The role of kynurenines in diabetes mellitus. Med Hypotheses 18:371–376CrossRefPubMedGoogle Scholar
  4. 4.
    Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13:465–477PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Alberati-Giani D, Ricciardi-Castagnoli P, Kohler C, Cesura AM (1996) Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem 66:996–1004CrossRefPubMedGoogle Scholar
  6. 6.
    Musajo L (1935) L’acido xanthurenico. Rend Accad Nazl Lincci 21:368–371Google Scholar
  7. 7.
    Mahuren JD, Dubeski PL, Cook NJ, Schaefer AL, Coburn SP (1999) Adrenocorticotropic hormone increases hydrolysis of B-6 vitamers in swine adrenal glands. J Nutr 129:1905–1908PubMedGoogle Scholar
  8. 8.
    Paul L, Ueland PM, Selhub J (2013) Mechanistic perspective on the relationship between pyridoxal 5′-phosphate and inflammation. Nutr Rev 71:239–244CrossRefPubMedGoogle Scholar
  9. 9.
    Rios-Avila L, Nijhout HF, Reed MC, Sitren HS, Gregory JF 3rd (2013) A mathematical model of tryptophan metabolism via the kynurenine pathway provides insights into the effects of vitamin B-6 deficiency, tryptophan loading, and induction of tryptophan 2,3-dioxygenase on tryptophan metabolites. J Nutr 143:1509–1519. doi: 10.3945/jn.113.174599 PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Kotake Y (1955) Xanthurenic acid, an abnormal metabolite of tryptophan and the diabetic symptoms caused in albino rats by its production. J Vitaminol (Kyoto) 1:73–87CrossRefGoogle Scholar
  11. 11.
    Ikeda S, Kotake Y (1984) Urinary excretion of xanthurenic acid and zinc in diabetes: 1) separation of xanthurenic acid-Zn2+ complex by ion-exchange chromatography. Acta Vitaminol Enzymol 6:23–28PubMedGoogle Scholar
  12. 12.
    Okamoto H (1981) Regulation of proinsulin synthesis in pancreatic islets and a new aspect to insulin-dependent diabetes. Mol Cell Biochem 37:43–61CrossRefPubMedGoogle Scholar
  13. 13.
    Murakami E, Kotake Y (1972) Studies on the xanthurenic acid-insulin complex. 3. Distribution of xanthurenic acid and formation of xanthurenic acid-insulin complex in serum. J Biochem 72:251–259PubMedGoogle Scholar
  14. 14.
    Meyramov G, Korchin V, Kocheryzkina N (1998) Diabetogenic activity of xanturenic acid determined by its chelating properties? Transplant Proc 30:2682–2684CrossRefPubMedGoogle Scholar
  15. 15.
    Oxenkrug G (2013) Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Mol Neurobiol 48:294–301. doi: 10.1007/s12035-013-8497-4 PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Oxenkrug GF, Turski WA, Zgrajka W, Weinstock JV, Summergrad P (2013) Tryptophan-kynurenine metabolism and insulin resistance in hepatitis C patients. Hepat Res Treat 2013: 149247Google Scholar
  17. 17.
    Manusadzhian VG, Kniazev IA, Vakhrusheva LL (1974) Mass spectrometric identification of xanthurenic acid in pre-diabetes. Vopr Med Khim 20:95–97PubMedGoogle Scholar
  18. 18.
    Midttun O, Ulvik A, Pedersen E, Ebbing M, Bleie O et al (2011) Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. J Nutr 141:611–617CrossRefPubMedGoogle Scholar
  19. 19.
    Marchetti P, Masiello P, Benzi L, Cecchetti P, Fierabracci V, Giannarelli R, Gregorio F, Brunetti P et al (1989) Effects of metformin therapy on plasma amino acid pattern in patients with maturity-onset diabetes. Drugs Exp Clin Res 15:565–570PubMedGoogle Scholar
  20. 20.
    Do MT, Kim HG, Tran TT, Khanal T, Choi JH, Chung YC, Jeong TC, Jeong HG (2014) Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression. Toxicol Appl Pharmacol 280:138–148. doi: 10.1016/j.taap.2014.07.021 CrossRefPubMedGoogle Scholar
  21. 21.
    Khattab M, Abul-Fadl M, Khalafallah A, Hamza S (1972) Studies on the urinary excretion of certain tryptophan metabolites in diabetics. J Egypt Med Assoc 55:531–541PubMedGoogle Scholar
  22. 22.
    Calandra P (1977) Identification of tryptophan metabolites in the healthy epidermis of diabetics. Acta Diabetol Lat 14:1426-37Google Scholar
  23. 23.
    Munipally PK, Agraharm SG, Valavala VK, Gundae S, Turlapati NR (2011) Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch Physiol Biochem 117:254–258. doi: 10.3109/13813455.2011.623705 CrossRefPubMedGoogle Scholar
  24. 24.
    Hayaishi O (1976) Properties and function of indoleamine 2,3-dioxygenase. J Biochem 79:13–21Google Scholar
  25. 25.
    Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G (2010) Neopterin, a prognostic marker in human malignancies. Cancer Lett 287:13–22CrossRefPubMedGoogle Scholar
  26. 26.
    Oxenkrug G, Tucker KL, Requintina P, Summergrad P (2011) Neopterin, a marker of interferon-gamma-inducible inflammation, correlates with pyridoxal-5′-phosphate, waist circumference, HDL-cholesterol, insulin resistance and mortality risk in adult Boston community dwellers of Puerto Rican origin. Am J Neuroprot Neuroregen 3:48–52PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Shibata K, Mushiage M, Kondo T, Hayakawa T, Tsuge H (1955) Effects of vitamin B6 deficiency on the conversion ratio of tryptophan to niacin. Biosci Biotechnol Biochem 59:2060–2063CrossRefGoogle Scholar
  28. 28.
    Yeh JK, Brown RR (1977) Effects of vitamin B-6 deficiency and tryptophan loading on urinary excretion of tryptophan metabolites in mammals. J Nutr 107:261–271PubMedGoogle Scholar
  29. 29.
    Bender DA, Njagi EN, Danielian PS (1990) Tryptophan metabolism in vitamin B6-deficient mice. Br J Nutr 63:27–36CrossRefPubMedGoogle Scholar
  30. 30.
    Midttun O, Ulvik A, Ringdal Pedersen E, Ebbing M, Bleie O, Schartum-Hansen H, Nilsen RM, Nygard O et al (2011) Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. J Nutr 141:611–617CrossRefPubMedGoogle Scholar
  31. 31.
    Pedersen ER, Tuseth N, Eussen SJ, Ueland PM, Strand E, Svingen GF, Midttun Ø, Meyer K et al (2015) Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol 35:455–462. doi: 10.1161/ATVBAHA.114.304674 CrossRefPubMedGoogle Scholar
  32. 32.
    Oxenkrug G, Ratner R, Summergrad P (2013) Kynurenines and vitamin B6: link between diabetes and depression. J Bioinformatics Diabetes 1:1–9. doi: 10.14302/issn.2374-9431.jbd-13-212 Google Scholar
  33. 33.
    Oxenkrug G (2015) 3-Hydroxykynurenic acid and type 2 diabetes: implications for aging, obesity, depression, Parkinson’s disease and schizophrenia. In: Engin A, Engin AB (eds) Tryptophan metabolism: implications for biological processes, health and diseases, molecular and integrative toxicology. Springer International Publishing, Switzerland, pp 173–195. doi: 10.1007/978-3-319-15630-9_8 Google Scholar
  34. 34.
    Polyzos KA, Ketelhuth DF (2015) The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease. An emerging field. Hamostaseologie 35:128–136. doi: 10.5482/HAMO-14-10-00562

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Psychiatry and Inflammation Program, Department of PsychiatryTufts University School of Medicine and Tufts Medical CenterBostonUSA

Personalised recommendations